Max Reinhardt Pacira Bio Sciences, Inc. (PCRX) insider trading activity

Max Reinhardt is President, Rest of World of Pacira BioSciences, Inc.. Currently has a direct ownership of 29,225 shares of PCRX, which is worth approximately $482,797. The most recent transaction as insider was on Jun 07, 2023, when has been sold 1,099 shares (Common Stock) at a price of $37.87 per share, resulting in proceeds of $41,619. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 29.2K

0% 3M change

0% 12M change

Total Value Held $482,797

MAX REINHARDT Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 07 2023	SELL Open market or private sale	$41,619 $37.87 p/Share	1,099 Reduced 3.62%	29,225 Common Stock
Jun 06 2023	SELL Open market or private sale	$41,095 $38.99 p/Share	1,054 Reduced 3.36%	30,324 Common Stock
Oct 07 2022	SELL Open market or private sale	$80,040 $58.0 p/Share	1,380 Reduced 4.21%	31,378 Common Stock
Jun 08 2022	BUY Grant, award, or other acquisition	-	7,950 Added 19.78%	32,250 Common Stock
Jun 07 2022	SELL Open market or private sale	$150,846 $62.0 p/Share	2,433 Reduced 9.07%	24,400 Common Stock
Jun 06 2022	SELL Open market or private sale	$172,879 $61.37 p/Share	2,817 Reduced 9.5%	26,833 Common Stock
Apr 21 2022	SELL Open market or private sale	$719,608 $73.25 p/Share	9,824 Reduced 24.89%	29,650 Common Stock
Apr 21 2022	BUY Exercise of conversion of derivative security	$531,750 $42.54 p/Share	12,500 Added 24.05%	39,474 Common Stock
Apr 20 2022	SELL Open market or private sale	$722,438 $73.99 p/Share	9,764 Reduced 26.58%	26,974 Common Stock
Apr 20 2022	BUY Exercise of conversion of derivative security	$531,750 $42.54 p/Share	12,500 Added 25.39%	36,738 Common Stock
Apr 19 2022	SELL Open market or private sale	$673,442 $72.25 p/Share	9,321 Reduced 27.77%	24,238 Common Stock
Apr 19 2022	BUY Exercise of conversion of derivative security	$531,750 $42.54 p/Share	12,500 Added 27.14%	33,559 Common Stock
Apr 18 2022	SELL Open market or private sale	$657,611 $73.55 p/Share	8,941 Reduced 29.8%	21,059 Common Stock
Apr 18 2022	BUY Exercise of conversion of derivative security	$531,750 $42.54 p/Share	12,500 Added 29.41%	30,000 Common Stock
Jul 02 2021	SELL Open market or private sale	$25,159 $59.76 p/Share	421 Reduced 2.35%	17,500 Common Stock
Jun 09 2021	BUY Grant, award, or other acquisition	-	7,000 Added 28.57%	17,500 Common Stock
Jun 07 2021	SELL Open market or private sale	$137,819 $60.5 p/Share	2,278 Reduced 17.83%	10,500 Common Stock
Jun 04 2021	SELL Open market or private sale	$74,591 $61.04 p/Share	1,222 Reduced 8.73%	12,778 Common Stock
Jan 06 2021	SELL Open market or private sale	$6,689 $60.81 p/Share	110 Reduced 0.78%	14,000 Common Stock
Nov 13 2020	SELL Open market or private sale	$1,577,250 $63.09 p/Share	25,000 Reduced 64.1%	14,000 Common Stock
Nov 13 2020	BUY Exercise of conversion of derivative security	$1,063,500 $42.54 p/Share	25,000 Added 39.06%	39,000 Common Stock

Also insider at

OFIX

Orthofix Medical Inc. Healthcare

President, Global Spine

Max Reinhardt

President, Rest of World

Tampa, FL

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PCRX shares.

Notify only if

Value

Insider Trading

Get notified when an Pacira Bio Sciences, Inc. insider buys or sells PCRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Pacira BioSciences, Inc.

Track Activities on PCRX

Account